William F. Novotny
168 works · 30,739 citations · h-index 44
Top works
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
- Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer
- Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
- Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial
- Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal Cancer
- Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
- Phase Ib Trial of Intravenous Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor in Combination With Chemotherapy in Patients With Advanced Cancer: Pharmacologic and Long-Term Safety Data
- Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab
- Impact of Vascular Endothelial Growth Factor-A Expression, Thrombospondin-2 Expression, and Microvessel Density on the Treatment Effect of Bevacizumab in Metastatic Colorectal Cancer
- Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor
- Regulation of coagulation by a multivalent Kunitz-type inhibitor
- Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial
- Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab
- Randomized Trial of an Oral Platelet Glycoprotein IIb/IIIa Antagonist, Sibrafiban, in Patients After an Acute Coronary Syndrome
- High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants
- First-line, single-agent Herceptin® (trastuzumab) in metastatic breast cancer
- Clinical pharmacokinetics of bevacizumab in patients with solid tumors
- Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma